Abbott Goes Full Throttle with Xience V

 

October 5, 2006

Abbott Vascular says it will begin launching its XIENCE V stent system immediately in most European countries, focusing commercial, manufacturing and clinical resources on this product.

"The positive, differentiating clinical results that XIENCE V demonstrated in SPIRIT II, combined with positive physician feedback about XIENCE V, indicates that XIENCE has significant potential to meet critical next- generation drug-eluting stent needs for physicians and patients," said John M. Capek, Ph.D., president, Cardiac Therapies, Abbott Vascular.

The company indicated it will not pursue commercialization of its ZoMaxx Drug-Eluting Coronary Stent System. Nevertheless, nine-month clinical data from ZOMAXX I, Abbott's international ZoMaxx trial, will be presented at the TCT scientific sessions in Washington D.C. on October 23, 2006.

For more information, visit www.abbott.com.

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.